Delving into the Latest Updates on Hepasome Pharmaceuticals, Inc. with Synapse

概览

关联

1

项与 Hepasome Pharmaceuticals, Inc. 相关的药物

Interferon alpha(Hepasome Pharmaceuticals)

靶点

IFNAR

作用机制

IFNAR激动剂

在研机构-

原研机构

Hepasome Pharmaceuticals, Inc.

在研适应症-

非在研适应症

丙型肝炎

最高研发阶段无进展

首次获批国家/地区-

首次获批日期-

1

项与 Hepasome Pharmaceuticals, Inc. 相关的临床试验

NCT00703872 / Unknown status临床2期

An Evaluation of Two Dose Routes of HDV-Interferon Administered With Ribavarin in the Treatment of Chronic Hepatitis C Nonresponders and Naive Hepatitis C Patients

A Phase II, Open Label, Multi-Center, Proof-Of-Concept Study determing whether treatment with HDV-Interferon (HDV-IFN), by oral or subcutaneous (injection) routes, and ribavirin results in similar efficacy [Rapid Virologic Response (RVR)] and safety as the reported efficacy and safety with pegylated alpha-interferon-2a and ribavirin (historical control) in patients with chronic hepatitis C (treatment naïve by oral route and non-responders by SC route respectively).

开始日期2008-05-01

申办/合作机构

Hepasome Pharmaceuticals, Inc.

100 项与 Hepasome Pharmaceuticals, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Hepasome Pharmaceuticals, Inc. 相关的专利（医药）

登录后查看更多信息

100 项与 Hepasome Pharmaceuticals, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Hepasome Pharmaceuticals, Inc. 相关的转化医学

登录后查看更多信息